Aspartoacylase suppresses prostate cancer progression by blocking LYN activation
ConclusionOur findings provide novel insights into the tumor-suppressive function of ASPA in PCa and highlight its potential as a prognostic biomarker and therapeutic target for the management of this malignancy.
Source: Military Medical Research - Category: International Medicine & Public Health Source Type: research
More News: Cancer | Cancer & Oncology | COVID-19 | International Medicine & Public Health | Prostate Cancer | Research | Statistics | Study | Universities & Medical Training